The Economics of Malaria Vaccine Development

Magdalena Plebanski; Katie L. Flanagan

doi:10.1016/j.pt.2017.01.006

The Economics of Malaria Vaccine Development

Magdalena Plebanski, Katie L. Flanagan

Research output: Contribution to journal › Comment / Debate › Other › peer-review

2 Citations (Scopus)

Abstract

Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS,S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).

Original language	English
Pages (from-to)	154-156
Number of pages	3
Journal	Trends in Parasitology
Volume	33
Issue number	3
DOIs	https://doi.org/10.1016/j.pt.2017.01.006
Publication status	Published - 1 Mar 2017

Access to Document

10.1016/j.pt.2017.01.006

Link to publication in Scopus

Cite this

@article{a54d2f2491bb406282472ba04b970d1e,

title = "The Economics of Malaria Vaccine Development",

abstract = "Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS,S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).",

author = "Magdalena Plebanski and Flanagan, {Katie L.}",

year = "2017",

month = mar,

day = "1",

doi = "10.1016/j.pt.2017.01.006",

language = "English",

volume = "33",

pages = "154--156",

journal = "Trends in Parasitology",

issn = "1471-4922",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - The Economics of Malaria Vaccine Development

AU - Plebanski, Magdalena

AU - Flanagan, Katie L.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS,S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).

AB - Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS,S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).

UR - http://www.scopus.com/inward/record.url?scp=85011416633&partnerID=8YFLogxK

U2 - 10.1016/j.pt.2017.01.006

DO - 10.1016/j.pt.2017.01.006

M3 - Comment / Debate

AN - SCOPUS:85011416633

VL - 33

SP - 154

EP - 156

JO - Trends in Parasitology

JF - Trends in Parasitology

SN - 1471-4922

IS - 3

ER -